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Introduction
Bacterial cells may produce several types of sub-
stances that inhibit the growth of other microorgan-
isms. These antimicrobial agents belong to different 
classes of molecules, ranging from the simple com-
pounds, like hydrogen peroxide or lactic acid to more 
complicated: antibiotics, peptides, exotoxins or lytic 
enzymes (Brito et al., 2011). Among them, the agents 
of proteinaceous nature, peptides and proteins, seem to 
be especially interesting. Bacteria produce two essential 
classes of products of this type: bacteriocins and pep-
tide antibiotics. Both of them are secreted to help the 
host strain to eliminate other microorganisms from the 
place of its growth. However, there are some important 
differences between these two classes of agents. First of 
all, enzymes synthesize the peptide antibiotics, whilst 
the bacteriocins are ribosomally synthesized. Bacterio-
cins are targeted at a narrow spectrum of bacteria often 
within the species of the producer or closely related 
ones, while the classical antibiotics are active against 
broad spectra of bacteria. Another important feature 
that separates bacteriocins from antibiotics is their 
potency against susceptible bacteria; bacteriocins are 
unique because they can kill bacteria at nanomolar 
concentrations, while antibiotics are needed in much 
higher concentrations (Nes, 2011). The bacteriocins are 
included in the larger group of antimicrobial substances 
defined as antimicrobial peptides (AMPs). These pep-
tides are ribosomally synthesized by all domains of 
living organisms (eukaryotes, bacteria and archaea). 
Similarly as bacteria the other organisms (e.g. plants, 
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A b s t r a c t
A collection of 206 Staphylococcus spp. isolates was investigated for their ability to produce compounds exhibiting antistaphylococcal activ-
ity. This group included Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus xylosus strains recovered from bovine mastitis 
(n = 158) and human skin wounds and soft tissues infections (n = 48). Production of substances with antimicrobial activity was observed in 
six strains. Five of them were recovered from bovine mastitis, and one was isolated from the infected human skin wound. Three of the six 
antimicrobials produced by the different strains showed substantial loss of antimicrobial activity upon treatment with proteolytic enzymes, 
which suggests their peptidic structure. Additional studies have shown that one of the putative bacteriocins was efficiently secreted to the 
liquid medium, facilitating its large-scale production and isolation. The peptide produced by the M2B strain exhibited promising activity; 
however, against narrow spectrum of Staphylococcus spp. clinical and animal isolates. Growth inhibition was observed only in the case 
of 13 (including nine S. aureus, three S. xylosus and one S. epidermidis strains) out of 206 strains tested. Important advantage of the produced 
agent was its high thermal stability. Fifteen minutes of incubation at 90°C did not affect its antimicrobial potential. The highest efficiency 
of production of the agent was demonstrated in TSB medium after 24 hours at 37°C. The researches revealed that ability to production 
of bacteriocin among staphylococci is not very common. Only one (S. xylosus strain assigned as M2B) out of 206 strains tested produced 
satisfactory amounts of antistaphylococcal bacteriocin. In spite of that, we would encourage other researchers for investigation of their 
collections of Staphylococcus spp. isolates towards selection strains producing antimicrobial agents.
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animals and humans) produce AMPs for elimination 
of pathogenic microorganisms and prevention of infec-
tions (AMPs constitute an important element of their 
innate immune system) (Rashid et al., 2016). AMPs 
such as human defensins, human neutrophil peptides 
and many bacterial bacteriocins are cationic and are 
able to bind to anionic parts of bacterial surface (e.g. 
anionic lipids or other anionic components) (Joerger, 
2003). AMP’s could undergo posttranslational modi-
fication e.g. proteolytic processing or glycosylation 
(Rashid et al., 2016).
The modes of action of AMPs, including most of 
the bacteriocins, involve interactions with the bacte-
rial cell membrane, and forming complexes with lipid II 
– a highly conserved precursor of the bacterial cell wall 
(Malanovic and Lohner, 2016). Cell membrane permea-
bilization leads to efflux of important intracellular mol-
ecules such as mono- and divalent ions (K+, Na+, Ca2+ 
and Mg2+) and ATP (Di Meo et al., 2016; Yeaman and 
Yount, 2003). Binding the peptides with lipid II inhibits 
peptidoglycan synthesis and additionally promotes pore 
formation and membrane disruption (Malanovic and 
Lohner, 2016). Structure-activity analyses of a broad 
range of peptides showed two main requirements for 
their antimicrobial activity: (1) a cationic charge and 
(2) an induced amphipathic conformation. The diver-
sity of lipids among pathogens could explain the differ-
ences in activity of a single peptide between different 
types of microorganisms (Powers and Hancock, 2003). 
Due to high selectivity and activity against a  sub-
stantial array of pathogenic microorganisms, AMP’s 
are a promising alternative to conventional antibacte-
rial antibiotics (Kosikowska and Lesner, 2016; Ołdak 
and Zielińska, 2017). Compared to conventional anti-
biotic therapy, killing of microorganisms by peptides 
is more rapid and they can ‘attack’ multiple molecular 
targets related to membrane and cell wall, which highly 
prevents development of resistant strains. However, 
the results of recent years revealed that many impor-
tant Gram-positive as well as Gram-negative bacteria, 
including dangerous human and animal pathogens, have 
developed mechanisms of modification of most impor-
tant molecular targets of AMPs, namely cell membrane 
and lipid II. As a consequence these strains are highly 
resistant to AMPs’ activity (Andersson et al., 2016).
In the present study, a collection of Staphylococcus 
spp. strains isolated from human skin wounds, soft tis-
sues infections, as well as from milk of bovine suffer-
ing from mastitis (S. aureus, S. epidermidis, S. xylosus) 
was screened for their ability to produce antibacterials, 
particularly with proteinaceous structure, with activity 
against other staphylococci. This research was focused 
on identification and preliminary characterization of 
the newly discovered antimicrobial peptides in order 
to uncover their potential therapeutic application in 
medicine and veterinary science for elimination of 
pathogenic bacteria from food products and also pos-
sibilities of their large-scale production. 
Experimental
Materials and methods
Bacterial strains. Staphylococcus spp. strains (n = 206) 
were isolated from milk of bovine suffering from mas-
titis (n = 158) (Jakubczak et al., 2007; Kot et al., 2012) 
and from human skin wounds and soft tissue infections 
(n = 48). Eighteen of the human derived isolates (col-
lected in 2013) were supplied by the Microbial Labo- 
ratory at the Provincial Hospital, Koszalin (Poland) 
and thirty strains were obtained from the Depart- 
ment of Clinical Microbiology, Central Hospital, Vaxjo 
(Sweden, collected between November 2006 and April 
2007) (Sjölund and Kahlmeter, 2008). All isolates of 
human origin were classified as S. aureus (n = 48) and 
strains isolated from milk belonged to three species: 
S. aureus (n = 120), S. epidermidis (n = 16) and S. xylosus 
(n = 22). The strains isolated from mastitis were col-
lected in two periods of time: between January 2005 
and December 2006 (90 isolates of S. aureus) and 
between February 2009 and March 2010 (all S. epider-
midis and S. xylosus and remaining S. aureus). Addi-
tionally Listeria monocytogenes and Micrococcus luteus 
strains were used as indicatory strains in antimicrobial 
activity assays. All strains were grown in liquid Tryp-
tic Soy Broth – TSB (Fluka) and on solid Tryptic Soy 
Agar – TSA (Tryptic Soy Broth + 1.5% agar (Sigma)). 
The strains were stored at –70°C as a cell suspension in 
PBS buffer (Phosphate Buffered Saline, pH 7.4; Sigma) 
containing 40% glycerol (vol/vol). 
Detection of AMP production. Production of anti- 
microbial substances by staphylococcal cells was evalu-
ated by the overlay method (Barefoot and Klaenhammer, 
1983; Fleming et al., 1975). The single colony (obtained 
by streaking on TSA agar plates) of the producing 
strains was transferred with a sterile needle or tooth-
pick on fresh TSA agar plates. After 24 hours of incuba-
tion at 37°C, the plates with a single, centrally located, 
colony – spot of potential producer strains were overlaid 
with soft TSA medium (Triptic Soy Broth supplemented 
with 0.75% Agar) inoculated with cells of the sensitive 
(indicator) strain to a final concentration of 0.01% (vol/
vol). Volume of the soft agar depended on the size of 
the plate, where soft agar should completely cover the 
surface of the bottom TSA medium and the producer 
strain colony. The indicator strains (n = 7) included six 
staphylococci strains isolated from animal infections 
(1 – S. xylosus, 1 – S. epidermidis and 4  –  S. aureus) 
and one strain of Listeria monocytogenes ATCC10425 
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(Table I). After inoculation, the plates were incubated 
at 37°C for another 24  h, and the growth inhibition 
of the indicator cells was determined. The presence of 
a clear zone around the producer strain colony con-
firmed production of an active antimicrobial agent. The 
diameter of the growth inhibitory zone was measured.
Antibacterial activity of the after-culture liquid 
medium was measured by the agar-well diffusion 
method (Schillinger and Lücke, 1989). The strains 
found as producers of antimicrobial agents on TSA 
agar plates (n = 6) were grown in TSB for 24 hours at 
37°C. The obtained cell suspensions were centrifuged 
(14 000 rpm, 10 min, room temperature) to collect 
the bacterial cells. The collected and filter sterilized 
(0.22 μm) supernatants (300 μl) were aliquoted into 
wells (diameter 7 mm) in solid TSA medium (TSB 
medium supplemented with 1.5% agar). The plates 
were dried in a laminar flow cabinet, and when the 
supernatant evaporated completely from the wells, the 
plates were overlaid with a soft agar layer inoculated 
with the cells of indicator strains to a final concentra-
tion of 0.01% (vol/vol). After incubation (24 h, 37°C), 
the diameters of clear zones were measured. 
Identification of the antimicrobials with protein-
aceus nature. The overlay method (described above, 
section – Detection of AMP production) was also used 
for identification of proteinaceus nature of antimicro-
bials produced by the selected strains. The 2 μl of solu-
tion of proteolytic enzymes (Pronase  E (20 mg/ml), 
α-Chymotrypsin (25 mg/ml) and Proteinase K (20 mg/
ml) (Lee et al., 2008)) were loaded on the surface of the 
bottom agar medium close to the growing colony of the 
producing strain – on the suspected border line of inhi-
bition growth zone of indicator strain. The prediction of 
the diameter of the growth inhibition zone was based on 
diameters of inhibition area from the results of previous 
analyses. The changing of the shape of growth inhibition 
zone – formation of so-called “half moon zone” near the 
colony of producing strain confirmed susceptibility of 
the produced agent to the proteolytic enzymes and that 
the secreted product had the proteinaceus nature. 
Determination of the activity spectrum of the 
identified AMPs. Determination of the potential anti-
microbial peptide activity spectrum was performed by 
the overlay method (as used in the previous tests, sec-
tion – Detection of AMP production) for the producer 
strains, which showed protease sensitivity (n = 3). All 
of the isolates from the collection of Department of 
Pharmaceutical Technology and Biochemistry, Gdansk 
University of Technology (n = 206) were used to define 
their susceptibility to the potential antimicrobial pep-
tide. The most sensitive strain (n = 1) was selected for 
investigation of the antimicrobial activity in further 
tests, e.g. the optimization of production or determi-
nation of thermostability.
Optimization of AMP production parameters. 
The conditions for the most effective production of 
the bacteriocins by the strains selected in the screen-
ing procedure were optimized in terms of: (1) medium 
type (Tryptic Soy Broth (TSB; DB Bioscience), Muel-
ler Hinton Broth (MHB; DB Bioscience), Brain Heart 
Infusion (BHI; DB Bioscience), Casamino acids (CAA; 
DB Bioscience) and Luria-Bertani (LB; BD Bioscience); 
(2) temperature (30°C, 35°C, 37°C), and (3) the growth 
period (12 h, 24 h and 48 h, 72 h). The cells were grown 
in suspension cultures with shaking (200 rpm). Samples 
of the cell suspensions were collected at time intervals 
(0 h, 3 h, 6 h, 9 h, 12 h, 24 h, 48 h, 72 h), centrifuged 
(10 000 rpm, 10 min, 4°C) and the activity of the super-
natants obtained was determined by the well – overlay 
method. The first step of the procedure was performed 
for all (n = 3) producer strains, which exhibited sensi-
tivity to proteolytic enzymes (S. xylosus M2B, S. epider-
midis 30c1 and S. aureus K1). After that step, we found 
out that only one antimicrobial peptide, produced by 
strain named M2B (S. xylosus), was efficiently secreted 
to liquid medium. Thus, other tests were performed 
only for this strain.
Determination of thermostability. Sample of the 
supernatant collected from the cultures after 24 h of 
antimicrobial-producing strain were incubated at 25°C, 
50°C, 65°C, 70°C, 75°C, 80°C, 85°C, 90°C for different 
1 S. xylosus 30c1 Bovine mastitis  ND
2 S. epidermidis 267 Bovine mastitis ND
3 S. aureus K10 Human skin wound (Koszalin) Susceptible
4 S. aureus 11 Bovine mastitis P, AMP, AML, S, AMC*
5 S. aureus 27 Bovine mastitis N, MY, S, E, DA*
6 S. aureus 101 (MRSA) Bovine mastitis P+DA+E+MY+S+N/OX*
7 L. monocytogenes ATCC10425 Reference strain  ND
Table I
The indicator strains used for preliminary selections of staphylococci producing antibacterial agents.
* – Resistance according to Szweda et al. 2014
Strain Source of the strain Resistance
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time periods (5 min, 10 min, 15 min, 30 min) and their 
activity was determined by the well-overlay method. 
Identification of the strain. Identification of the 
producing strain M2B was carried out by sequencing 
of 16S rRNA gene. PCR amplification of the target gene 
was carried out with a pair of primers:
rP1 5’ CCCGGGATCCAAGCTTAGAGTTTGATC-
CTGGCTCAG 3’
fD2 5’ CCGAATTCGTCGACAACACGGCTACCTT-
GTTACGACTT 3’
following the method described by the group of Weis-
burg (1991). Sequencing of the amplified product was 
carried out by Macrogen (The Netherlands). The analy-
sis of sequence was performed with using MEGA 6.1 
(Molecular Evolutionary Genetics Analysis) software.
Results
Screening of the 206 bacterial isolates resulted in 
the identification of six strains producing antistaphylo- 
coccal agents. Three producing strains were S. aureus 
isolated from bovine mastitis (assigned in the collec-
tion as 30, 31 and 32), one was S. aureus recovered from 
human skin wound (K1), one agent was produced by 
S. xylosus M2B and the last of producing strain was 
S. epidermidis 30c1. The antibacterial activity of three 
(produced by S. aureus 30, 31 and 32) out of six sub-
stances was not affected by the treatment with pro-
teolytic enzymes, suggesting their non-proteinaceous 
structure. Further tests eliminated two additional 
strains (K1 and 30c1), since they produced antimicro-
bial substances exclusively when grown on solid (agar) 
medium while no antibacterial activity was detected 
in the supernatants collected from the suspension cul-
tures. Therefore, completion of the screening procedure 
resulted in the identification of one strain effectively 
producing the antibacterial substance with protease-
sensitive structure, i.e. potential bacteriocin or peptide 
antibiotic. This strain (M2B) and the produced agent 
were the subjects of further analysis. 
Based on the sequence of the gene coding for 16S 
rRNA, the producing strain was identified as S. xylo-
sus (99,9% of identity of this gene sequence with the 
sequences of 16S rRNA genes of other bacteria of the 
this genus) – labeled in the collection as M2B. The 
antimicrobial agent synthesized by this strain was effi-
ciently produced both on solid as well as in a liquid 
medium (Fig. 1a and Fig. 2) and its’ activity was elimi-
nated in the presence of proteases (Fig. 3).
The antimicrobial spectrum of the putative antimi-
crobial peptide produced by S. xylosus M2B was deter-
mined by the well overlay method. Growth inhibition 
zones were observed with 13 strains of staphylococci 
(including nine S. aureus, three S. xylosus and one 
S. epidermidis strains), L. monocytogenes and M. luteus 
(Table  II). Diameters of the growth inhibitory zones 
were in the range of 12–25 mm; surprisingly appar-
ent substantial differences in sensitivity to the putative 
AMPs were found among the different S. aureus strains.
Conditions for the effective production of the puta-
tive bacteriocin by S. xylosus M2B in a liquid culture 
were optimized in the terms of medium type, time 
period and incubation temperature. Comparison of 
Fig. 1. Growth inhibition zone around the colony of producer
strain M2B; an indicator strain – S. aureus 30C1.
Fig. 2. Formation of “half moon zone” near the colony
of producer strain M2B in the presence of proteolytic enzyme;
an indicator strain – L. monocytogenes.
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the production efficiency in five different commercially 
available media, recommended for staphylococci cul-
ture, revealed that the optimal production of the puta-
tive AMP was observed in TSB medium. Slightly lower 
level of peptide production was found in MHB and LB 
media and no production was detected in CAA and 
BHI media (Fig. 2).
The maximum level of AMP production by S. xylo-
sus M2B was observed after 24 h of incubation in TSB 
medium, and the optimal temperature was 37°C. 
The tests of thermostability revealed that the puta-
tive antimicrobial peptide did not lose its activity after 
15 minutes of heating at 90°C. After 30 min of incuba-
tion in 90°C peptide lost its activity (inhibition zone 
was significantly smaller).
Discussion
Studies on the antimicrobial substances produced 
by staphylococci, have not been very extensive so far. 
However, there are a few peptides exhibiting antista- 
phylococcal activity produced by bacteria that belong 
to this genus, including both CNS – coagulase nega-
tive and CPS – coagulase positive staphylococci. The 
most promising examples of AMPs produced by CNS 
are the following bacteriocins: Pep5, epicidin 280, 
epilancin K7, epidermin, nukacin ISK-1, simulancin 
3299, and the most extensively characterized bac-
teriocins produced by CPS are: staphylococcin C55, 
aureocin A70, aureocin A53 (Nascimento et al., 2006; 
Varella Coelho et al., 2007). The detailed characteristics 
of the best characterized staphylococcins has been pre-
sented in the review by Bastos and coworkers (Bastos 
et al., 2009). The authors also emphasized that staphy-
lococcins may be applied, solely or in a combination 
with other chemical agents. The use of combinations 
of antimicrobials is common in the clinical setting, 
and the most important advantages coming from such 
approach are: 1)  expanding the spectrum of organ-
isms that can be targeted, 2) prevention of the emer-
gence of resistant organisms, 3) decreasing of toxicity 
by allowing lower doses of both agents (Kurlenda and 
Grinholc, 2012).
Our studies, results of which are presented in this 
work, are probably one of the very few examples of an 
extensive screening aimed at the identification of anti-
microbial peptides produced by staphylococci isolated 
from humans (skin and soft tissue infections n = 48) 
or animals (strains isolated from bovine with mastitis 
n = 158). From the set of 206 strains, we identified six 
strains producing any antimicrobials (2.9%), of which, 
one was confirmed to be a putative peptide or protein 
with antimicrobial activity, efficiently produced in 
a liquid medium. Two out of three antimicrobial – pro-
ducing strains identified in these studies did not pro-
duce the antimicrobial agents at the detectable level 
when grown in liquid media. Similar problems were 
recently observed by Braem and coworkers (2014), 
who identified Staphylococcus chromogenes L217 strain 
(isolated from teat apices of dairy cows) producing 
nukacin-like bacteriocin displaying a broad spectrum 
of antimicrobial activity. Unfortunately, the bacteriocin 
was only produced in significant quantities when the 
producer strain was grown on solid agar medium.
 1  7 (S. aureus) 12
 2  11 (S. aureus) 20
 3  28 (S. aureus) 15
 4  52 (S. aureus) 22
 5  68 (S. aureus) 25
 6  77 (S. aureus) 18
 7  92 (S. aureus) 17
 8  99 (S. aureus) 25
 9 115 (S. aureus) 15
10 83A (S. epidermidis) 15
11   8J (S. xylosus) 15
12 30C1 (S. xylosus) 15
13 247 (S. xylosus) 15
14 L. monocytogenes 15
15 M. luteus 15
Table II
Activity of newly identified agent against strains
from the Departments’ collection.
No.
of strain
Code number
of the sensitive strain
Growth inhibition
zone [mm]
Fig. 3. Antimicrobial activity of the after-culture liquid media
after growth of the producer strain.
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The molecular structure of the putative AMP pro-
duced by S. xylosus M2B is not known until now. This 
work is in progress in our laboratory, but preliminary 
results indicate that it could be a novel, previously 
undescribed compound. Its antimicrobial spectrum is 
interesting, since it is relatively narrow. Additionally, 
the good thermostability is advantageous, which could 
be especially important in the case of potential appli-
cation of the identified antimicrobial peptide for the 
elimination of staphylococci from food products, but 
also for purification procedure, e.g. preliminary separa-
tion of the peptide from other components of the cell 
free after-culture supernatant by the heat treatment.
The produced peptide exhibits also strong activity 
against other important foodborne pathogenic bacteria 
L. monocytogenes. Thus, it could be also applied for pro-
tection of food products against these bacteria. 
The recent studies carried out by Hewelt-Belka and 
coworkers (2016) revealed some important differences 
in the lipid composition of S. aureus clinical isolates. 
The observed, by the mentioned authors, differences 
in the lipid patterns between sensitive and resistant 
S. aureus strains suggest that antibiotic susceptibility 
may be associated with the lipid composition of bacte-
rial cells. The lipids that were found to significantly dif-
fer between antibiotic-resistant and antibiotic-sensitive 
clinical isolates are involved in the biosynthesis of major 
S. aureus membrane lipids and lipoteichoic acid. The 
research of Powers and Hancock (2003) revealed that 
the lipid composition of the bacterial cell membrane 
is crucial for AMPs activity. Thus the observed in our 
studies differences in the susceptibility of Staphylococ-
cus spp. strains tested to the agent produced by M2B 
can be caused by some differences in the lipid composi-
tion of their cell membranes. 
In our studies, the prevalence of isolation of strains 
producing AMPs was found to be at a relatively low 
level – below 2% (three out of 206 isolates), and only 
one strain (prevalence below 0.5%) produced a peptide 
that is worthy of further studies. However, we do not 
have any doubts that staphylococci represents an inter-
esting and promising source of uncharacterized anti-
microbial peptides, which could be used for treatment 
or prophylaxis of infections caused by other bacteria 
that belong to the Staphylococcus spp. but also other 
important pathogenic microorganisms e.g. L. monocy-
togenes. Unfortunately, the research in this field is lim-
ited. Each year, numerous publications concerning the 
antibiotic resistance of the staphylococci isolated from 
both, human and animal (especially bovine mastitis) 
infections from different world regions are presented. 
In the case of some of these publications, large popula-
tions, counting even several hundreds of isolates, are 
investigated. Unfortunately, very few of these isolates 
are investigated for their potential production of anti-
microbial agents. The methods used for screening the 
‘producing strains’ are relatively easy and could be per-
formed in most of microbiological laboratories. Thus, 
we encourage other research groups, which have access 
to the large number of human or animal isolates of 
staphylococci, for investigation of the production abil-
ity of potential antimicrobial peptides by these strains.
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